California State Teachers Retirement System Sells 40,972 Shares of Gilead Sciences, Inc. $GILD

California State Teachers Retirement System decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,914,292 shares of the biopharmaceutical company’s stock after selling 40,972 shares during the period. California State Teachers Retirement System’s holdings in Gilead Sciences were worth $266,795,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the fourth quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its position in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 85 shares during the last quarter. Quattro Advisors LLC bought a new position in shares of Gilead Sciences during the 4th quarter worth $26,000. Wealth Preservation Advisors LLC grew its stake in shares of Gilead Sciences by 60.0% during the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 81 shares during the period. Finally, Ares Financial Consulting LLC purchased a new stake in Gilead Sciences in the 4th quarter worth about $28,000. 83.67% of the stock is owned by institutional investors.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $125.40, for a total transaction of $376,200.00. Following the sale, the chief financial officer owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. This represents a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This represents a 18.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 67,000 shares of company stock valued at $8,687,140. Corporate insiders own 0.30% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley maintained an Overweight rating on Gilead and only modestly reduced its price target to $165 from $166, implying substantial potential upside based on the recent trading level. The endorsement supports sentiment toward Gilead’s valuation and outlook. Benzinga analyst update
• Positive Sentiment: Gilead’s shares outperformed the market during the latest session, suggesting investors may be responding to the company’s defensive profile, strong profitability and established product portfolio. Its most recent reported quarter exceeded consensus estimates for both earnings and revenue, providing a supportive backdrop. Gilead Sciences outperforms the market
• Neutral Sentiment: Broader biopharmaceutical industry developments, including digital bioprocessing and prediction-market discussions related to drug research, do not appear to create a direct near-term catalyst for Gilead. Bioprocessing Summit 2026
• Negative Sentiment: Zacks expects Gilead to report a decline in upcoming earnings and says the company lacks the combination of positive earnings revisions and estimates typically associated with a likely earnings beat. This could limit upside or increase volatility ahead of the results. Gilead earnings expectations

Gilead Sciences Stock Up 2.9%

Shares of NASDAQ GILD opened at $134.32 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The business has a 50-day simple moving average of $129.64 and a two-hundred day simple moving average of $135.75. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The company has a market cap of $166.77 billion, a P/E ratio of 18.30 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same period in the prior year, the business posted $1.81 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts anticipate that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on GILD shares. Wall Street Zen raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Leerink Partners downgraded shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Gilead Sciences in a research report on Monday, July 6th. Daiwa Securities Group dropped their price target on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 19th. Finally, Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a report on Wednesday, May 20th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $158.30.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.